首页 | 本学科首页   官方微博 | 高级检索  
     


Invited Review Recognition and management of angiotensin converting enzyme inhibitor fetopathy
Authors:Aileen B. Sedman  David B. Kershaw  Timothy E. Bunchman
Affiliation:1. Pediatric Nephrology Service, University of Michigan Medical Center, Simpson Road East, Box 0297-L2602, 1521, Ann Arbor, MI, 48109-0297, USA
Abstract:Angiotensin converting enzyme (ACE) inhibitors are extensively used for the treatment of hypertension, to decrease proteinuria, and to mitigate hyperfiltration. These drugs now have been shown to be fetotoxic causing profound fetal hypotension, renal tubular dysplasia, anuria-oligohydramnios, growth restriction, hypocalvaria, and death when used in the second and third trimesters of pregnancy. We recommend that ACE inhibitors not be used in pregnancy. However, if a child is born with ACE inhibitor fetopathy, aggressive therapy with dialysis to remove the inhibitor may mitigate the profound hypotensive effects. Therapy will depend on the specific ACE inhibitor, and care recommendations cannot be generalized for the entire class of drugs as their protein binding and volume of distribution differ substantially.
Keywords:Angiotensin converting enzyme inhibitors  Fetopathy  Therapy
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号